scholarly journals Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma

2020 ◽  
pp. 20200354
Author(s):  
Claire Timlin ◽  
James Loken ◽  
Jon Kruse ◽  
Robert Miller ◽  
Uwe Schneider

Objectives: To assess if Excess Absolute Risk (EAR) of radiation-induced solid cancer can be used to rank radiotherapy plans for treatment of Hodgkin Lymphoma (HL) in a statistically significant way. Methods: EAR models, calibrated with data from the Life Span Study and HL survivors, have been incorporated into a voxelised risk-calculation software, which is used to compare four treatment modalities planned for five virtual HL patients. Organ-specific parameters are generated repeatedly in a Monte Carlo fashion to model their uncertainties. This in turn enables a quantitative estimation of the EAR uncertainties. Results: Parameter driven uncertainties on total EAR are around 13%, decreasing to around 2–5% for relative EAR comparisons. Total EAR estimations indicate that Intensity Modulated Proton Therapy decreases the average risk by 40% compared to the Intensity Modulated Radiation Therapy plan, 28% compared to the Volumetric Modulated Arc Therapy plan whereas the 3D Conformal Radiation Therapy plan is equivalent within the uncertainty. Conclusions: Relative EAR is a useful metric for distinguishing between radiotherapy plans in terms of second cancer risk. Advances in knowledge: Relative EAR is not dominated by model or parameter uncertainties and can be used to guide the choice of radiotherapy for HL patients.

2014 ◽  
Vol 62 (2) ◽  
pp. 311-316 ◽  
Author(s):  
Dana L. Casey ◽  
Danielle N. Friedman ◽  
Chaya S. Moskowitz ◽  
Patrick D. Hilden ◽  
Charles A. Sklar ◽  
...  

2018 ◽  
Vol 100 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Andrea Riccardo Filippi ◽  
Valentina Vanoni ◽  
Bruno Meduri ◽  
Luca Cozzi ◽  
Marta Scorsetti ◽  
...  

2018 ◽  
Vol 182 (2) ◽  
pp. 208-214 ◽  
Author(s):  
Michalis Mazonakis ◽  
Stefanos Kachris ◽  
John Damilakis

2012 ◽  
Vol 84 (3) ◽  
pp. S420-S421
Author(s):  
M.R. Folkert ◽  
M.J. Zelefsky ◽  
A. Fidaleo ◽  
D.R. Feldman ◽  
G.J. Bosl ◽  
...  

2012 ◽  
Vol 39 (6Part2) ◽  
pp. 3601-3601
Author(s):  
K Homann ◽  
R Howell ◽  
A Giebeler ◽  
J Eley ◽  
K Randeniya ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8039-8039
Author(s):  
Michael Schaapveld ◽  
Berthe M Aleman ◽  
Anja M Eggermond ◽  
Cecile P Janus ◽  
Augustinus Krol ◽  
...  

8039 Background: During the last decades Hodgkin Lymphoma (HL) treatment changed towards less toxic chemotherapy schemes and smaller radiation fields. The impact of these changes on second cancer (SC) risk is still unknown. Methods: We calculated standardized incidence ratios (SIR), comparing SC risk after HL treatment with expected risk, based on cancer incidence in the general population, and compared SC risk between treatment modalities, accounting for competing events, in a large Dutch cohort comprising 3,390 5-years HL survivors, aged 15-51 years at HL treatment and diagnosed between 1965-2000. Results: The median follow-up was 18.2 years; 23% of the patients was followed ≥25 years. During follow-up 734 SCs and 92 third cancers (TC) occurred. The SIR for any SC was 4.5 (95% confidence interval (95%CI) 4.1-4.9). SC risk was still elevated after 35 years of follow-up (SIR 3.9; 95%CI 2.5-5.8) and cumulative incidence (CI) reached 47.1% (95%CI 43.6-50.5) at 40 years follow-up. For TCs the SIR was 5.5 (95%CI 4.4-6.9); the 20-year CI was 22.3% (95%CI 17.8-27.2). Risks of NHL and leukemia strongly decreased in more recent treatment periods (P-trend <0.001). The CI of solid tumors (ST) between 5-19 years after HL treatment did not differ for patients treated between 1965-1979, 1980-1989 or 1990-2000 (P=0.21; 19-year CI 9.1%, 11.6% and 11.4%, respectively). Radiotherapy (RT) above the diaphragm increased risk of STs above the diaphragm (hazard ratio (HR) 2.4, P<0.001), while subdiaphragmatic RT was associated with a 1.7-fold increased HR of a subdiaphragmatic ST (P=0.001). An incomplete mantle field was associated with significantly lower breast cancer (BC) risk (hazard ratio (HR) 0.4, 95%CI 0.2-0.8). A cumulative procarbazine dose >4.2 g/m2 yielded a 1.3-fold increased HR (95%CI 1.0-1.7) for non-breast STs and a 2-fold (95%CI 1.2-3.1) increased HR for gastrointestinal STs, but was associated with a strongly decreased BC risk (HR 0.3, 95%CI 0.2-0.6). Conclusions: SC risk after HL has decreased with treatment changes over the last decades, due to strongly decreasing risk of leukemia and NHL. Smaller radiation fields and procarbazine doses >4.2 g/m2 are associated with lower breast cancer risk, while high procarbazine doses increase risk of gastrointestinal STs.


Sign in / Sign up

Export Citation Format

Share Document